



DFW

# CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: Julie A. Dalla

Signature: Julie A. Dalla Date: 10/05/2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

<b>Supplemental Information Disclosure Statement</b>  <b>Address to:</b> <b>Commissioner of Patents</b> <b>PO Box 1450</b> <b>Alexandria, VA 22313-1450</b>	<b>First Named Inventor</b>	Dewdney, et al.
	<b>Application Number</b>	10/824,980
	<b>Filing Date</b>	April 15, 2004
	<b>Group Art Unit</b>	1624
	<b>Examiner</b>	Cecilia M. Jaisle
	<b>Attorney Docket No.</b>	R0164B-REG
	<b>Title</b>	SUBSTITUTED 7-AZA- QUINAZOLINE COMPOUNDS USEFUL AS P38 KINASE INHIBITORS

Sir:

### Transmittal for Supplemental Information Disclosure Statement

Transmitted herewith for filing in the above-entitled patent application is an Information Disclosure Statement, in compliance with 37 CFR §1.97, which may be material to the patentability of the subject patent application.


- [X] Attached are:
- Form 1449, "Information Disclosure Statement By Applicant(s)," with copy of each reference cited
  - Return postcard
- [X] The Information Disclosure Statement is being submitted more than three (3) months after the filing date and after the mailing date of the first Office Action on the merits, but before a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first, without certification under 37 CFR 1.97(e). Therefore, only if this entry is checked in the left margin, the \$180.00 fee set forth in § 1.17(p) is authorized below.
- [X] The Commissioner is hereby authorized to charge **\$180.00** Deposit Account 18-1700.

10/11/2006 HLE333 00000017 181700 10824980

01 FC:1806 180.00 DA

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Grant D. Green  
Reg. No. 31,259  
Attorney for Applicant(s)

Roche Palo Alto LLC  
Patent Law Dept.  
3431 Hillview Avenue - M/S A2-250  
Palo Alto, CA 94304  
Direct Phone (650) 855-5311

Date: 10/5/06



PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT(S)**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/824,980
Filing Date	April 15, 2004
First Named Inventor	Dewdney, Nolan James
Art Unit	1624
Examiner Name	Cecilia M. Jaisle
Attorney Docket Number	R0164B-REG

**U.S. PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				

**OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	LEE, J.C., et al., "p38 Mitogen-Activated Protein Kinase Inhibitors Mechanisms and Therapeutic Potentials," <i>Pharmacol. Ther.</i> 82 (1999) 389-397.	
	C2	NEWTON, R., et al., "New aspects of p38 mitogen activated protein kinase (MAPK) biology in lung inflammation," <i>Drug Discovery Today</i> 3 (2006) 53-61	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

143136